These findings indicate that combined treatment of CCA cells with ABC294640 and sorafenib leads to more effective suppression of pro-survival STAT3 signaling and inhibition of cancer cell growth than either agent alone. The gene discussed is STAT3; the disease is cholangiocarcinoma.